|
|
Analysis of the Effect of Cyclosporine on Gallstone Formation in Patients with Aplastic Anemia |
JI Tongying, LI Gonghui, WANG Yingfen |
Zhujiang Hospital,Southern Medical University, Guangdong Guangzhou 510000, China |
|
|
Abstract Objective: To analyze the effect of cyclosporine on cholelithiasis in a population of patients with aplastic anemia. Methods: Two hundred and sixty-three patients with aplastic anemia admitted to our hospital from January 2016 to May 2022 were selected and divided into 103 cases in the anti-thymocyte globulin group (ATG group) and 160 cases in the cyclosporine group (CsA group) according to the immunosuppressive treatment regimen.Liver function and lipids were measured in peripheral blood laboratory after admission and after receiving 6 months of treatment,and cholestasis and stone formation in the biliary system were examined by color Doppler ultrasound in all patients. Results: The incidence of cholestasis in the ATG group was 5.83% and the incidence of stones was 2.91%; the incidence of cholestasis in the CsA group was significantly higher in the CsA group than in the ATG group (P<0.05,P<0.05); there was no significant difference in liver function between the two groups (P>0.05); the incidence of dyslipidemia was 2.91% in the ATG group and 9.38% in the CsA group during the same treatment cycle.The incidence of dyslipidemia in patients in the CsA group was significantly higher than that in the ATG group (P<0.05). Conclusion: Cholelithiasis can be secondary to the treatment of aplastic anemia with cyclosporine,among which gallbladder sediment stones are common,and the generation of stones may be closely related to cholestasis caused by cyclosporine,and CsA can cause dyslipidemia in patients.
|
|
|
|
|
[1] 王蕊,董彩丽,赵云婷,等.Treg/Th17细胞失衡及相关细胞因子表达水平与再生障碍性贫血的关系分析[J].河北医学,2020,26(10):1738-1742. [2] 曾军杰,刘丽娜,房佰俊.三氧化二砷联合环孢霉素A治疗再生障碍性贫血的疗效分析[J].郑州大学学报(医学版),2018,53(4):496-499. [3] 党青华,罗君,王敏,等.miR-1260b经MAPK/ERK途径促进再生障碍性贫血小鼠骨髓造血功能恢复[J].中国实验诊断学,2022,26(12):1816-1822. [4] 史忆萌,张凤奎.再生障碍性贫血免疫抑制治疗进入三药时代[J].中国实用内科杂志,2022,42(10):836-841. [5] Stief J,Stempfle HU,Gotzberger M,et al.Biliary diseases in heart transplanted patients:a comparison between cyclosporine A versus tacrolimus-based immunosuppression[J].Eur Med Res,2009,14(5):206-209. [6] 王蕊,董彩丽,赵云婷,等.Treg/Th17细胞失衡及相关细胞因子表达水平与再生障碍性贫血的关系分析[J].河北医学,2020,26(10):1738-1742. [7] 郭媛媛.养血饮联合环孢素A治疗再生障碍性贫血临床观察[J].西部中医药,2020,33(7):121-124. [8] DeZern AE,Churpek JE.Approach to the diagnosis of aplastic anemia[J].Blood Adv,2021,5(12):2660-2671. [9] Peslak SA,Olson T,Babushok DV.Diagnosis and treatment of aplastic anemia[J].Curr Treat Options Oncol,2017,18(12):70. [10] 张慧敏,袁丽倩,史奎竹,等.雄激素对再生障碍性贫血患者端粒长度影响的研究[J].河北医科大学学报,2020,41(1):54-57. [11] 娜日苏.环孢素A与雄激素规范化治疗再生障碍性贫血的疗效及不良反应发生率分析[J].中国标准化,2022,617(20):291-293. [12] 叶春桃.环孢素血药浓度水平对慢性再生障碍性贫血免疫抑制治疗近期疗效的影响研究[J].中国处方药,2021,19(12):116-118. [13] 杨冠群,刘晓庆,杨慧,等.环磷酰胺联合泼尼松治疗环孢菌素难治/复发的大颗粒淋巴细胞白血病相关纯红细胞再生障碍[J].临床血液学杂志,2023,36(1):39-43. [14] 曾珊珊,向阳.环孢素不良反应与再生障碍性贫血疗效相关性回顾性分析[J].山西医药杂志,2021,50(4):595-597. [15] Kohri K,Yasui T,Okada A,et al.Biomolecular mechanism of urinary stone formation involving osteopontin[J].Urol Res,2012,40(6):623-637. [16] Kimak E,Solski J,Baranowicz-Gaszczyk I,et al.A long-term study of dyslipidemia and dyslipoproteinemia in stable post-renal transplant patients[J].Ren Fail,2006;28(6):483-486. |
|
|
|